Combined general meeting of may 22, 2025 - availability of the preparatory documents

Daix (france), new york city (new york, united states), april 30,  2025 – inventiva (euronext paris and nasdaq: iva), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“mash”), also known as non-alcoholic steatohepatitis (“nash”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the combined general meeting of may 22, 2025.
GM Ratings Summary
GM Quant Ranking